CardieX Limited (AU:CDX) has released an update.
CardieX Limited reported a significant 137% increase in revenue for FY 2024, totaling $10.9 million, largely attributed to the early completion of a multi-year clinical trial. Despite this revenue surge, the company still registered a net loss, although reduced by 60% to $7.6 million compared to the previous year. The balance sheet improved with a strengthened net asset position, but no dividends were declared for the period.
For further insights into AU:CDX stock, check out TipRanks’ Stock Analysis page.
